Research Article
The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
Table 2
Clinical outcomes of hospitalized patients with COVID-19 pneumonia.
| | Variables | Nintedanib group (n=21) | Control group (n=21) | Mean difference (95% CI) | value |
| | SpO2/FiO2 ratio difference between before and after treatment | 144.38 ± 118.05 | 55.67 ± 75.09 | 88.71 (26.66 to 105.76) | 0.006 | | Length of hospital stay, days | 35.48 ± 15.92 | 38.57 ± 18.32 | −3.10 (−13.80 to 7.61) | 0.562 | | Oxygen improvement | 15 (71.4) | 14 (66.7) | NA | 0.739 | | Chest X-ray improvement | 15 (71.4) | 14 (66.7) | NA | 0.739 | | Mortality at 60 days after first admission | 8 (38.1) | 5 (23.8) | NA | 0.317 | | Duration of antifibrotic treatment, days | 17.86 ± 10.89 | 0 ± 0 | 17.85 (12.89 to 22.81) | <0.001 |
| | Adverse event | | Hepatitis | 2 (9.5) | 0 (0) | NA | 0.488 | | Loss of appetite | 2 (9.5) | 0 (0) | NA | 0.488 | | Diarrhea | 1 (4.8) | 0 (0) | NA | 1.000 |
|
|
Data shown as n (%) or mean ± SD. NA=not applicable; SpO2/FiO2=oxygen saturation to fraction of inspired oxygen.
|
